Elderly with Chronic Kidney Disease Benefit from SGLT2 Inhibitors, Study Shows

Just now November 3, 2026 1 min read 📰 Medical Xpress

📋 Key Takeaway

A study presented at the American Society of Nephrology's Kidney Week indicates that SGLT2 inhibitors significantly benefit elderly patients with chronic kidney disease. This research could influence healthcare policies and treatment options for the aging population in Iran. Understanding these advancements is crucial for improving health outcomes in similar demographics.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors show significant benefits for adults aged 80 years and older with chronic kidney disease (CKD), according to a study presented at Kidney Week, the annual meeting of the American Society of Nephrology, held from Oct. 21 to 25 in Denver.